Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2764772 | 1.00 | ATM (0.37) | ATMKCNK3ALDH1A1THRBCNR2 | |
| SCHEMBL2764775 | 1.00 | ATM (0.37) | ATMKCNK3ALDH1A1THRBCNR2 | |
| Vsn-16R SCHEMBL17049466 | 0.97 | ATM (0.38) | ATMKCNK3ALDH1A1THRBCNR2 | |
| Vsn-16R SCHEMBL2135092 | 0.97 | ATM (0.38) | ATMKCNK3ALDH1A1THRBCNR2 | |
| Vsn-16R SCHEMBL15896536 | 0.97 | ATM (0.38) | ATMKCNK3ALDH1A1THRBCNR2 | |
| Vsn-16R SCHEMBL2623648 | 0.97 | ATM (0.38) | ATMKCNK3ALDH1A1THRBCNR2 | |
| Vsn-16R SCHEMBL1725527 | 0.97 | ATM (0.38) | ATMKCNK3ALDH1A1THRBCNR2 | |
| Vsn-16R SCHEMBL2763494 | 0.97 | ATM (0.38) | ATMKCNK3ALDH1A1THRBCNR2 | |
| Vsn-16R SCHEMBL1725526 | 0.97 | ATM (0.38) | ATMKCNK3ALDH1A1THRBCNR2 | |
| SCHEMBL2765429 | 0.93 | ATM (0.39) | ATMALDH1A1MAP4K4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| WO-2016128771-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
| US-20160107984-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2016-04-21 | — | — | US | disclosed |
| US-20160107984-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2016-04-21 | — | — | US | disclosed |
| US-9120723-B2 | Modulator | CANBEX THERAPEUTICS LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-9120723-B2 | Modulator | CANBEX THERAPEUTICS LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-9024067-B2 | Process for preparing carboxylic acid amides useful in the treatment of muscular disorders | CANBEX THERAPEUTICS LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| US-9024067-B2 | Process for preparing carboxylic acid amides useful in the treatment of muscular disorders | CANBEX THERAPEUTICS LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| US-20130123356-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2013-05-16 | — | — | US | disclosed |
| US-20120101301-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | UCL BUSINESS PLC (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101301-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | UCL BUSINESS PLC (GB) | 2012-04-26 | — | — | US | disclosed |
| WO-2010116116-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | UCL BUSINESS PLC (GB) | 2010-10-14 | — | — | WO | disclosed |
| US-20100144876-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100144876-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2010-06-10 | — | — | US | disclosed |
| EP-2177503-A1 | MODULATORS OF CANNABINOID RECEPTORS | UCL Business PLC (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-7696382-B2 | Modulator | UNIVERSITY COLLEGE LONDON (GB) | 2010-04-13 | — | — | US | disclosed |
| US-7696382-B2 | Modulator | UNIVERSITY COLLEGE LONDON (GB) | 2010-04-13 | — | — | US | disclosed |
| US-20080114062-A1 | Modulator | UNIVERSITY COLLEGE LONDON WOLFSON INSTITUTE FOR BIOMEDICAL RESEARCH (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114062-A1 | Modulator | UNIVERSITY COLLEGE LONDON WOLFSON INSTITUTE FOR BIOMEDICAL RESEARCH (GB) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114062-A1 | Modulator | CHRNA3, CHRM3, NR3C2 | ATM 4322/4885KCNK3 720/4885ALDH1A1 3425/4885 |
| US-20160107984-A1 | MODULATOR | CHRNA3, CHRNB3, CHRM3 | ATM 4443/4885KCNK3 510/4885ALDH1A1 4349/4885 |
| US-20130123356-A1 | MODULATOR | MRGPRX2, NR3C2, MC2R | ATM 4751/4885KCNK3 1574/4885ALDH1A1 1637/4885 |
| US-20120101301-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | CPT1B, MUSK, C1R | ATM 3139/4885KCNK3 1308/4885ALDH1A1 1230/4885 |
| US-20100144876-A1 | MODULATOR | CHRNA3, CHRM3, NR3C2 | ATM 4322/4885KCNK3 720/4885ALDH1A1 3425/4885 |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | HCN4, KCNJ4, KCNQ4 | ATM 3547/4885KCNK3 40/4885ALDH1A1 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.